VOLUNTARY ANNOUNCEMENT Favorable Phase II Efficacy Data of GFH375 (Oral KRAS G12D Inhibitor) Monotherapy in Pretreated NSCLC Presented in Oral Session at 2026 World Conference on Lung Cancer (WCLC)
Filed with HKEX · Stock code 2595 · · 4 pages · English
GenFleet Therapeutics (Shanghai) Inc. 勁方醫藥科技(上海)股份有限公司 (A joint stock company incorporated in the People’s Republic of China with limited liability) (Stock Code: 2595) VOLUNTARY ANNOUNCEMENT Favorable Phase II Efficacy Data of GFH375 (Oral KRAS G12D Inhibitor) Monotherapy in Pretreated NSCLC Presented in Oral Session at 2026 World Conference on Lung Cancer (WCLC) This announcement is made by GenFl
Genfleet Therapeutics (Shanghai), Inc. on 6ix
Earlier from Genfleet Therapeutics (Shanghai)
Later from Genfleet Therapeutics (Shanghai)
- 2026 Interim Report
- VOLUNTARY ANNOUNCEMENT Announcement on the Progress of Share Repurchase
- Announcement pursuant to rule 13.10 of the listing rules
- VOLUNTARY ANNOUNCEMENT Disclosure Arrangements for Clinical Data from Studies of GFH375 and GFH276
- Resignation of non-executive director
Follow Genfleet Therapeutics (Shanghai) into a list and get an email when it puts out news.
Follow Genfleet Therapeutics (Shanghai)